Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4436584
Max Phase: Preclinical
Molecular Formula: C16H17ClN6O5S2
Molecular Weight: 472.94
Molecule Type: Unknown
Associated Items:
ID: ALA4436584
Max Phase: Preclinical
Molecular Formula: C16H17ClN6O5S2
Molecular Weight: 472.94
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Nc1ncnc2c1c(Sc1cccc(Cl)c1)nn2[C@H]1C[C@H](O)[C@H](COS(N)(=O)=O)O1
Standard InChI: InChI=1S/C16H17ClN6O5S2/c17-8-2-1-3-9(4-8)29-16-13-14(18)20-7-21-15(13)23(22-16)12-5-10(24)11(28-12)6-27-30(19,25)26/h1-4,7,10-12,24H,5-6H2,(H2,18,20,21)(H2,19,25,26)/t10-,11-,12+/m0/s1
Standard InChI Key: OICGDVPCZSVSCO-SDDRHHMPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 472.94 | Molecular Weight (Monoisotopic): 472.0390 | AlogP: 1.08 | #Rotatable Bonds: 6 |
Polar Surface Area: 168.47 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.33 | CX Basic pKa: 3.44 | CX LogP: 1.61 | CX LogD: 1.61 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.47 | Np Likeness Score: -0.51 |
1. (2018) Atg7 inhibitors and the uses thereof, |
2. Huang SC,Adhikari S,Brownell JE,Calderwood EF,Chouitar J,D'Amore NR,England DB,Foley K,Harrison SJ,LeRoy PJ,Lok D,Lublinsky A,Ma LT,Menon S,Yang Y,Zhang J,Gould AE. (2020) Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors., 28 (19): [PMID:32912429] [10.1016/j.bmc.2020.115681] |
Source(2):